Magnitude of peroxisome proliferator-activated receptor-γ activation is associated with important and seemingly opposite biological responses in breast cancer cells

Journal of Investigative Medicine

Volumn 49, Issue 5, 2001, Pages 413-420

  Clay, C E ^a   Namen, A M ^a   Atsumi, G I ^a   Trimboli, A J ^a   Fonteh, A N ^a   High, K P ^a   Chilton, F H ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Breast cancer; Cell cycle arrest; Differentiation; PPAR

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; CD36 ANTIGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN DERIVATIVE; TROGLITAZONE; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; TRANSCRIPTION INITIATION; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL PROLIFERATION; DOSE RESPONSE; MDA-MB-231 CELL LINE; S PHASE CELL CYCLE CHECKPOINT;

EID: 0034889267     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/6650.2001.33786     Document Type: Article

References (52)

1. The peroxisome proliferatoractivated receptors: Ligands and activators
2. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids
3. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
4. Peroxisome proliferators and peroxisome proliferator activated receptors (PPAR) as regulators of lipid metabolism
5. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ
6. mPPARγ2: Tissue-specific regulator of an adipocyte enhancer
7. Peroxisome proliferator-activated receptor (PPAR) gamma: Adipose-predominant expression and induction early in adipocyte differentiation
8. Stimulation of adipogenesis in fibroblast by PPARγ2, a lipid activated transcription factor
9. cDNA cloning, chromosomal mapping and functional characterization of the human peroxisome proliferator activated receptor
10. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ
11. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ
12. Activation of human peroxisome proliferator- activated receptor by the antitumor agent phenylacetate and its analogs
13. An antidiabetic thiazolinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ)
14. 2 is a ligand for adipocyte determination factor PPARγ
15. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation
16. Activators of peroxisome proliferator-activated receptor γ have depotspecific effects on human preadipocyte differentiation
17. 2-mediated cellular arrest and death
18. 2
19. 1 analogs that suppress tumor cell growth through induction of p21 and reduction of cyclin E
20. Convergence of 9-cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors
21. Transactivation by retinoid X receptor-peroxisome proliferator-activated receptor γ (PPARγ) heterodimer: Intermolecular synergy requires only the PPARγ hormone-dependent activation function
22. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptors heterodimers with ligands, coactivators, and corepressors
23. Interactions controlling the nuclear-receptor heterodimers and co-activators
24. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and retinoid X receptor
25. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisomes proliferator-activated receptors by coactivator-dependent receptor ligand assay
26. 1 and activation with retinoid X receptor agonist and antagonists
27. Price TM. MCF-7 and T47D human breast cancer cells contain a functional peroxisomal response
28. Ligands for peroxisomes proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice
29. Terminal differentiation of human breast cancer through PPARγ
30. The nuclear eicosanoid receptor PPARγ is aberrantly expressed in colonic tumors
31. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-γ agonist through induction of apoptosis
32. Ligand for peroxisome proliferator-activated receptor-γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo
33. Peroxisome proliferator-activated receptor γ induces growth arrest and differentiation markers of human colon cancer cells
34. Min/+ mice
35. Activators of the nuclear receptor PPARγ enhance colon polyp formation
36. Differentiation and reversal of malignant changes in colon cancer through PPARγ
37. PPARγ and colorectal carcinoma: Conflicts in a nuclear family
38. Paclitaxel-induced apoptotic changes followed by timelapse video microscopy in cell lines established from head and neck cancer
39. Major DNA fragmentation is a late event in apoptosis
40. Characterization of radiation-induced apoptosis in rodent cell lines
41. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells
42. A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolinedione drugs
43. Transdifferentiation of myoblast by the adipogenic transcription factors PPAR gamma and C/EBP alpha
44. Cathespin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays
45. Fatty acid composition and CD36 expression in breast adipose tissue of premenopausal and postmenopausal women
46. Inhibition of breast cancer progression by an antibody to a thrombospondin-I receptor
47. Tamoxifen in early breast cancer
48. Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor alpha (PPARα)
49. Roles of PPARs in health and disease
50. 2
51. 1 → S transition in vascular smooth muscle cells
52. Ligand type-specific interactions of peroxisome proliferator-activated receptor γ with transcriptional coactivators